Raltitrexed
LCKY2016-65
Approved small_molecule active
Quick answer
Raltitrexed for Head and Neck Squamous Cell Carcinoma is a Approved program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Head and Neck Squamous Cell Carcinoma
- Phase
- Approved
- Modality
- small_molecule
- Status
- active